Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Nov 1;208(9):1386-90.
doi: 10.1093/infdis/jit342. Epub 2013 Aug 1.

Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine

Myron J Levin  1 , Kenneth E Schmader, John W Gnann, Shelly A McNeil, Timo Vesikari, Robert F Betts, Susan Keay, Jon E Stek, Nickoya D Bundick, Shu-Chih Su, Yanli Zhao, Xiaoming Li, Ivan S F Chan, Paula W Annunziato, Janie Parrino
Affiliations
Randomized Controlled Trial

Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine

Myron J Levin et al. J Infect Dis. .

Abstract

Prevaccination and 6-week postvaccination samples from the immunogenicity substudy (n = 2269) of the zoster vaccine (ZV) efficacy trial (N = 22 439) in 50-59-year-old subjects were examined for varicella-zoster virus-specific antibody responses to vaccination. The varicella-zoster virus geometric mean titer (GMT) and geometric mean fold rise were higher in ZV recipients than in placebo recipients (GMT, 660.0 vs 293.1 glycoprotein enzyme-linked immunosorbent assay units/mL [P < .001], respectively; geometric mean fold rise, 2.31 vs 1.00 [P < .025]). In each group there was a strong inverse correlation between postvaccination GMT and risk of subsequent herpes zoster. Although these data provide strong evidence that relates ZV-induced antibody and the risk of herpes zoster, a protective threshold was not determined. Clinical Trials Registration. NCT00534248.

Keywords: herpes zoster; immunogenicity; zoster vaccine.

PubMed Disclaimer

References

    1. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271–84. - PubMed
    1. Harpaz R, Ortega-Sanchez IR, Seward JF. Advisory committee on immunization practices (ACIP) centers for disease control and prevention (CDC). Prevention of herpes zoster: Recommendations of the advisory committee on immunization practices (ACIP) MMWR Recomm Rep. 2008;57(RR-5):1–30. - PubMed
    1. Oxman MN. Zoster vaccine: current status and future prospects. Clin Infect Dis. 2010;51:197–213. - PubMed
    1. Hata A, Asanuma H, Rinki M, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med. 2002;347:26–34. - PubMed
    1. Arvin AM, Pollard RB, Rasmussen LE, Merigan TC. Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections with lymphoma. J Clin Invest. 1980;65:869–78. - PMC - PubMed

Publication types

Associated data